There are currently 1519 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
Recruiting
Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such as trauma, tumors or infection. Whereas post-traumatic defects are the largest group. Reports estimate that there are almost 4 million bone grafting procedures worldwide per year. However, limb reconstruction in the context of a bony defect is challenging and up to date... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Limb Fracture, Bone Loss
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Recruiting
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Carcinoma, Non-Small Cell Lung
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
Recruiting
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective but safer than remaining on intravenous (IV) antibiotic therapy for the duration of treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland +1 locations
Conditions: Gram-negative Bacteremia
Phase I Nab-Paclitaxel Plus Gemcitabine with Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
Recruiting
The purpose of this study is to determine the maximum tolerated dose of the chemotherapy drugs nab-paclitaxel and gemcitabine when combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer. You will receive proton therapy once a day (Monday - Friday) for 3 weeks. Participants will also receive chemotherapy on each Monday of those three weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/18/2025
Locations: University of Maryland Medical Center/Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Locally Advanced Pancreatic Cancer
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
Recruiting
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland +1 locations
Conditions: Glioma, Glioblastoma, Brain Tumor
OMEGA - Dietary Intervention - COPD Trial
Recruiting
A randomized controlled trial of a food delivery dietary intervention targeting increased omega-3 intake to determine whether dietary modifications can improve Chronic Obstructive Pulmonary Disease (COPD) outcomes and attenuate the adverse effects of particulate matter on respiratory health. Investigators believe that study results will comprehensively address the impact of an evidence-based nutrition intervention on COPD health and provide a framework for dietary intervention within other chro... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/18/2025
Locations: Johns Hopkins Bayview Campus, Baltimore, Maryland
Conditions: COPD, Chronic Obstructive Pulmonary Disease
Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels
Recruiting
Acute normovolemic hemodilution (ANH) is performed as a blood conservation technique during surgical procedures with high risk for significant blood loss. It is done by taking out some of the patients blood before surgery actually begins and storing this blood inside of the operating room and giving it back to the patient at the end of surgery when most of the expected surgical bleeding has already occurred. This practice reduces the amount of bleeding that occurs after surgery and also reduces... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/18/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Acute Kidney Injury
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Gorlin Syndrome
VTP-1000 in Adults with Celiac Disease
Recruiting
GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/18/2025
Locations: Parexel EPCU Baltimore, Baltimore, Maryland
Conditions: Celiac Disease
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
Recruiting
The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland +1 locations
Conditions: Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Recruiting
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Cerebral Adrenoleukodystrophy (cALD)
Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
Recruiting
800 adult first time kidney transplant recipients will be enrolled in the Observational Study and followed to evaluate their Human Leukocyte Antigen (HLA)-DR/DQ molecular mismatch (mMM) score as a risk-stratifying prognostic biomarker. Six months after transplant the study will identify those who meet the eligibility criteria for the Nested Randomized Control Trial (RCT). 300 eligible subjects will be randomized 2:1 to abatacept or Standard of care (SOC) in the randomization and followed for 18... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/17/2025
Locations: Johns Hopkins Hospital:Transplantation, Baltimore, Maryland
Conditions: Kidney Transplant